{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360025439370616576.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.20944/preprints202309.1062.v1"}},{"identifier":{"@type":"DOI","@value":"10.3390/ijms242015473"}},{"identifier":{"@type":"PMID","@value":"37895151"}}],"resourceType":"preprint","dc:title":[{"@value":"Metabolic-Dysfunction Associated Steatotic Liver Disease -Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Ideal Treatments"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Metabolic-dysfunction associated steatotic liver disease (MASLD) is a chronic liver disease that affects more than a quarter of the global population, and is increasing worldwide, due to the pandemic of obesity. Insulin resistance is closely associated with the development and progression of MASLD. Hepatic entry of increased fatty acids (FA) released from adipose tissue, increase in FA synthesis and reduced FA oxidation in the liver, and hepatic overproduction of triglyceride (TG)-rich lipoproteins may induce the development of MASLD. Since insulin resistance also induces atherosclerosis, the leading cause for death in MASLD patients is cardiovascular disease (CVD). Considering that the development of CVD determines the prognosis of MASLD patients, the ideal therapeutic interventions for MASLD should reduce body weight, improve coronary risk factors, in addition to an improvement in liver functiom. Lifestyle modification such as diet and exercise and surgical interventions such as bariatric surgery and intragastric balloons have shown to improve MASLD by reducing body weight. Sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to improve coronary risk factors and to suppress the occurrence of CVD. Both SGLT2i and GLP-1 have been reported to improve liver enzymes, hepatic steatosis and fibrosis. We recently reported that the selective peroxisome proliferator-activated receptor-alpha (PPARα) modulator, pemafibrate, improved liver function. PPARα agonists have multiple anti-atherogenic properties. Here, we consider the pathophysiology of MASLD and the mechanisms of action of such drugs, and consider whether such drugs and the combination therapy of such drugs could be the ideal treatments for MASLD.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380025439370616576","@type":"Researcher","foaf:name":[{"@value":"Hidekatsu Yanai"}]},{"@id":"https://cir.nii.ac.jp/crid/1380025439370616704","@type":"Researcher","foaf:name":[{"@value":"Hiroki Adachi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380025439370616577","@type":"Researcher","foaf:name":[{"@value":"Mariko Hakoshima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380025439370616705","@type":"Researcher","foaf:name":[{"@value":"Sakura Iida"}]},{"@id":"https://cir.nii.ac.jp/crid/1380025439370616706","@type":"Researcher","foaf:name":[{"@value":"Hisayuki Katsuyama"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"14220067"}],"prism:publicationName":[{"@value":"International Journal of Molecular Sciences"}],"dc:publisher":[{"@value":"MDPI AG"}],"prism:publicationDate":"2023-09-18","prism:volume":"24","prism:startingPage":"15473"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://creativecommons.org/licenses/by/4.0"],"createdAt":"2023-09-18","modifiedAt":"2023-10-30","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Fatty%20Liver","dc:title":"Fatty Liver"},{"@id":"https://cir.nii.ac.jp/all?q=Cardiovascular%20Diseases","dc:title":"Cardiovascular Diseases"},{"@id":"https://cir.nii.ac.jp/all?q=Fatty%20Acids","dc:title":"Fatty Acids"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=PPAR%20alpha","dc:title":"PPAR alpha"},{"@id":"https://cir.nii.ac.jp/all?q=Review","dc:title":"Review"},{"@id":"https://cir.nii.ac.jp/all?q=Obesity","dc:title":"Obesity"},{"@id":"https://cir.nii.ac.jp/all?q=Insulin%20Resistance","dc:title":"Insulin Resistance"},{"@id":"https://cir.nii.ac.jp/all?q=Atherosclerosis","dc:title":"Atherosclerosis"},{"@id":"https://cir.nii.ac.jp/all?q=Sodium-Glucose%20Transporter%202%20Inhibitors","dc:title":"Sodium-Glucose Transporter 2 Inhibitors"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360025430195451136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1881429166239299072","@type":"Dataset","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Faculty Opinions recommendation of Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass."}]},{"@id":"https://cir.nii.ac.jp/crid/1882272492636934400","@type":"Dataset","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Faculty Opinions recommendation of The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity."}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.20944/preprints202309.1062.v1"},{"@type":"OPENAIRE","@value":"doi_dedup___::12c756194789278e67afdcdd695a4e07"},{"@type":"CROSSREF","@value":"10.3390/cells14060428_references_DOI_8DB2Ca9JXv1TmUscv4jZqnb4Oqf"}]}